BTIG Research Reaffirms Buy Rating for Embecta (NASDAQ:EMBC)

BTIG Research restated their buy rating on shares of Embecta (NASDAQ:EMBC) in a report published on Friday morning,Benzinga reports. They currently have a $25.00 target price on the stock.

EMBC has been the topic of a number of other reports. Wall Street Zen raised Embecta from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 16th. Zacks Research raised shares of Embecta from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 26th. Finally, Mizuho dropped their target price on shares of Embecta from $13.00 to $12.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 16th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $19.00.

Embecta Trading Up 2.0%

Embecta stock opened at $14.78 on Friday. Embecta has a 12 month low of $9.20 and a 12 month high of $21.48. The company has a market capitalization of $864.54 million, a PE ratio of 10.34, a P/E/G ratio of 0.83 and a beta of 1.11. The stock has a 50-day moving average price of $11.89 and a two-hundred day moving average price of $11.85.

Embecta (NASDAQ:EMBC) last released its earnings results on Friday, August 8th. The company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.77 by $0.35. Embecta had a negative return on equity of 23.40% and a net margin of 7.58%.The business had revenue of $295.50 million during the quarter, compared to analysts’ expectations of $278.15 million. During the same quarter last year, the firm posted $0.74 earnings per share. The firm’s revenue was up 8.4% on a year-over-year basis. Embecta has set its FY 2025 guidance at 2.900-2.950 EPS. As a group, analysts predict that Embecta will post 2.85 earnings per share for the current fiscal year.

Embecta Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 15th. Stockholders of record on Friday, August 29th will be paid a $0.15 dividend. The ex-dividend date of this dividend is Friday, August 29th. This represents a $0.60 annualized dividend and a dividend yield of 4.1%. Embecta’s payout ratio is currently 41.96%.

Institutional Trading of Embecta

A number of institutional investors have recently added to or reduced their stakes in EMBC. Northern Trust Corp lifted its stake in Embecta by 10.5% in the fourth quarter. Northern Trust Corp now owns 700,972 shares of the company’s stock valued at $14,475,000 after acquiring an additional 66,367 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in Embecta in the fourth quarter valued at approximately $156,000. Deutsche Bank AG raised its position in shares of Embecta by 40.8% in the fourth quarter. Deutsche Bank AG now owns 56,110 shares of the company’s stock valued at $1,159,000 after purchasing an additional 16,249 shares during the period. Meros Investment Management LP raised its position in shares of Embecta by 30.2% in the fourth quarter. Meros Investment Management LP now owns 247,312 shares of the company’s stock valued at $5,107,000 after purchasing an additional 57,312 shares during the period. Finally, ProShare Advisors LLC raised its position in shares of Embecta by 44.5% in the fourth quarter. ProShare Advisors LLC now owns 17,464 shares of the company’s stock valued at $361,000 after purchasing an additional 5,376 shares during the period. 93.83% of the stock is currently owned by institutional investors and hedge funds.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.